



Press release

Great success of the exercise of warrants

Dijon, 6 July 2022

CROSSJECT (ISIN: FR0011716265; Ticker: ALCJ), a specialty pharma company that is developing and will soon be marketing a portfolio of combined drugs for use in emergency situations, announces the results of the exercise of warrants issued and allocated free of charge on 5 January 2022.

On 5 January 2022, Crossject issued and allocated free warrants to all existing shareholders at the rate of 1 warrant per share held, with 20 warrants entitling the holder to subscribe for 1 share at a price of €3.00.

At the end of the warrant exercise period, which expired after trading on 30 June 2022, 18,808,300 warrants had been exercised, representing 940,415 new Crossject shares issued for a total of €2,821,245. The new shares carry current dividend rights and have been listed on the same line as the existing shares. Warrants not exercised by 30 June 2022 after the close of trading have lapsed.

The proceeds from the exercise of the warrants, the receipt of the research tax credit in June, milestones on contracts already signed and upcoming billings under the BARDA contract will all make major contributions to financing the Company's activity and development. As indicated in the press release dated 24 March 2022, Crossject will continue to adapt its future financing methods (commercial revenues, contributions from strategic partners, grants and subsidies, or financial transactions).

Patrick Alexandre, Crossject CEO, said: *"On behalf of all the teams at Crossject, I would like to thank the shareholders who showed their support by participating massively in the transaction. Since the start of the year, Crossject has made significant announcements, including the signing of a contract with the US Department of Health and Human Services, (BARDA). We are all fully mobilised to achieve our mission of Saving Lives Simply."*



Next release: 20 September 2022 (after trading): First-half 2022 results

Contacts:

Crossject
Patrick Alexandre
info@crossject.com

Investor relations
CIC Market Solutions
Catherine Couanau +33 (0)1 53 48 81 97
catherine.couanau@cic.fr

Press relations
Buzz & Compagnie
Mélanie Voisard +33 (0)3 80 43 54 89
melanie.voisard@buzzetcompagnie.com
Christelle Distinguin +33 (0)3 80 43 54 89
christelle.distinguin@buzzetcompagnie.com

About CROSSJECT • www.crossject.com

Crossject (ISIN: FR0011716265; Ticker: ALCJ; LEI: 969500W1VTFNL2D85A65) is developing and is soon to market a portfolio of drugs dedicated to emergency situations: epilepsy, overdose, allergic shock, severe migraine and asthma attack. Thanks to its patented needle-free self-injection system, Crossject aims to become the world leader in self-administered emergency drugs. The company has been listed on the Euronext Growth market in Paris since 2014, and benefits from Bpifrance funding.